首页> 外文期刊>Pharmacology Research & Perspectives >Relative bioavailability and pharmacokinetic comparison of calcium glucoheptonate with calcium carbonate
【24h】

Relative bioavailability and pharmacokinetic comparison of calcium glucoheptonate with calcium carbonate

机译:碳酸钙钙葡萄糖酸钙的相对生物利用度和药代动力学比较

获取原文
       

摘要

Adequate calcium intake is important for the prevention of bone loss and osteoporosis. For some populations such as those of Southeast Asia where calcium intake is very low, supplements represent a suitable dietary source of calcium. The objective of this study was to compare the relative oral bioavailability of calcium from calcium glucoheptonate, a highly soluble calcium salt containing 8.2% of elemental calcium, to that of calcium carbonate. A single-dose, randomized-sequence, open-label, twoperiod crossover study, with a 7-day washout period, was conducted in 24 Indonesian healthy adult volunteers. After a 12-hour (overnight) fast, subjects received either two oral ampoules of 250 mg/10 mL of calcium glucoheptonate each or one effervescent tablet of calcium carbonate containing 500 mg of elemental calcium. The relative oral bioavailability of calcium from calcium glucoheptonate as compared to calcium carbonate was 92% within 6 hours and 89% within 12 hours after study drug administration. The 90% confidence intervals for the mean test/reference ratios of the maximum plasma concentration and the area under the concentration-time curve at 12 hours post-administration were 77.09%–120.31% and 60.58%–122.30%, respectively. Five subjects experienced a total of eight adverse events which were all mild and transient; no serious adverse events or deaths were reported. These results indicate that calcium glucoheptonate is associated with a high relative bioavailability of calcium compared to calcium carbonate, and is well-tolerated. Calcium glucoheptonate might thus be a potential choice for calcium supplementation in Southeast Asian populations.
机译:足够的钙摄入是预防骨质损失和骨质疏松症的重要性。对于诸如东南亚的一些人群,钙摄入量非常低,补充代表了合适的膳食钙来源。本研究的目的是将钙的钙酸钙,含有8.2%的元素钙的高度可溶性钙盐,碳酸钙的高度可溶性钙盐进行比较钙的相对口服生物利用度。单剂量,随机序列,开放标签,双倍体交叉研究,在24个印度尼西亚健康成人志愿者中进行了7天的洗涤期。在12小时(过夜)快速后,受试者接受了250mg / 10ml钙葡萄糖酸钙的两种口腔细胞,每种或一种含有500mg元素钙的碳酸钙的泡腾片剂。与碳酸钙钙钙酸钙的相对口服生物有效性与碳酸钙相比,在研究药物施用后12小时内在6小时内为92%和89%。对于最大血浆浓度的平均试验/参考比的90%置信区间和在给药后12小时内浓缩时间曲线下的面积分别为77.09%-120.31%和60.58%-12.30%。五个受试者共有八种不良事件,这些不良事件都是轻度和短暂的;没有报告任何严重的不良事件或死亡。这些结果表明,与碳酸钙相比,钙葡聚糖酸钙与钙的高相对生物利用度有关,并且具有良好的耐受性。因此,Glucohoptopate钙可能是东南亚人群钙补充剂的潜在选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号